Nixon Peabody Trust Co. Sells 3,167 Shares of IQVIA Holdings Inc. $IQV

Nixon Peabody Trust Co. reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.0% during the second quarter, Holdings Channel reports. The institutional investor owned 60,656 shares of the medical research company’s stock after selling 3,167 shares during the quarter. Nixon Peabody Trust Co.’s holdings in IQVIA were worth $9,559,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Verdence Capital Advisors LLC bought a new stake in IQVIA during the 2nd quarter valued at $3,612,000. Patton Fund Management Inc. purchased a new position in IQVIA during the 2nd quarter valued at about $231,000. Heritage Investors Management Corp raised its holdings in shares of IQVIA by 10.5% during the second quarter. Heritage Investors Management Corp now owns 104,704 shares of the medical research company’s stock valued at $16,500,000 after acquiring an additional 9,909 shares in the last quarter. Private Advisor Group LLC lifted its stake in IQVIA by 11.6% in the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock worth $958,000 after acquiring an additional 566 shares during the period. Finally, Nordea Investment Management AB boosted its holdings in IQVIA by 41.7% in the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after acquiring an additional 606,391 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 1.1%

IQVIA stock opened at $223.36 on Friday. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $228.12. The stock has a fifty day simple moving average of $202.05 and a two-hundred day simple moving average of $178.04. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The firm has a market cap of $38.04 billion, a price-to-earnings ratio of 30.64, a PEG ratio of 2.47 and a beta of 1.34.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. During the same period last year, the firm posted $2.84 earnings per share. IQVIA’s revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on IQV shares. William Blair reiterated an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Barclays upped their target price on IQVIA from $185.00 to $200.00 and gave the stock an “equal weight” rating in a report on Thursday, October 2nd. Truist Financial restated a “buy” rating and issued a $265.00 target price (up previously from $235.00) on shares of IQVIA in a research note on Wednesday, October 29th. Cowen cut IQVIA from a “buy” rating to a “hold” rating in a research note on Monday, November 3rd. Finally, Redburn Partners set a $214.00 price objective on IQVIA in a research report on Wednesday, September 3rd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $241.00.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.